A recently published consensus statement on PSMA PET/CT response assessment criteria in prostate cancer states that an increase of tumour volume > 30% should be considered progressive disease in polymetastatic prostate cancer, while an incomplete reduction of ≥ 30% should be called partial response [21]. This evidence concerns the gene FOLH1 and Familial prostate cancer.